| Field | Specification |
|---|---|
| Target | |
| Alternative names | Isoleucine--tRNA ligase, mitochondrial; Isoleucyl-tRNA synthetase; IleRS; IARS2 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derivedhumanIARS2recombinantprotein(Position:D702-K1012).HumanIARS2?shares?84.2%?amino?acid?(aa)?sequence?identity?withmouseIARS2. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes isoleucine--tRNA ligase, mitochondrial (gene IARS2) in human, mouse and rat samples and is validated for Western blot, IHC, flow cytometry and ELISA. The predicted molecular weight is 113.8 kDa, and the supplier reports an observed band at about 114 kDa.
IARS2 is the mitochondrial isoleucyl-tRNA synthetase, which loads isoleucine onto mitochondrial tRNA for the synthesis of proteins encoded by the mitochondrial genome. It is essential for oxidative phosphorylation, and it is studied in mitochondrial translation and related inherited disorders.
| Target | Isoleucine--tRNA ligase, mitochondrial (gene IARS2; UniProt Q9NSE4, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 113.8 kDa |
| Observed MW | 114 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.25 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Mouse, Rat) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HeLa cells, human 293T cells, human A549 cells, human A431 cells, human Hacat cells, human HepG2 cells, rat brain tissue, rat kidney tissue, mouse brain tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.25 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human esophageal squamous carcinoma tissue, human placenta tissue, human rectum adenocarcinoma tissue, mouse kidney tissue, rat kidney tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): 293T cells.
Immunogen
E. coli-derivedhumanIARS2recombinantprotein(Position:D702-K1012).HumanIARS2?shares?84.2%?amino?acid?(aa)?sequence?identity?withmouseIARS2.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places isoleucine--tRNA ligase, mitochondrial in the mitochondrion matrix. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
